Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
19.3 AUD | +0.10% | -5.39% | -22.71% |
03:34am | Neuren Pharmaceuticals' Medication Secures Priority Review from Health Canada | MT |
Feb. 29 | Neuren Pharmaceuticals Limited Provides Sales Guidance for the First Quarter and Full Year 2024 | CI |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-22.71% | 1.58B | |
+26.88% | 659B | |
+27.09% | 557B | |
-5.03% | 359B | |
+16.73% | 322B | |
+9.51% | 297B | |
+6.04% | 215B | |
+5.30% | 210B | |
-6.05% | 200B | |
-8.46% | 149B |
- Stock Market
- Equities
- NEU Stock
- News Neuren Pharmaceuticals Limited
- Neuren Pharmaceuticals' Partner Secures US FDA Approval for Rett Syndrome Treatment